PPDI » Topics » SIGNATURES

This excerpt taken from the PPDI 8-K filed Oct 27, 2009.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Pharmaceutical Product Development, Inc.
Date: October 27, 2009   By:  

/S/    DANIEL DARAZSDI        

  Name:   Daniel Darazsdi
  Title:   Chief Financial Officer
This excerpt taken from the PPDI 8-K filed Jul 22, 2009.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Pharmaceutical Product Development, Inc.
Date: July 21, 2009   By:  

/s/ Daniel Darazsdi

  Name:   Daniel Darazsdi
  Title:   Chief Financial Officer
This excerpt taken from the PPDI 10-Q filed May 5, 2009.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

PHARMACEUTICAL PRODUCT DEVELOPMENT, INC.

  (Registrant)
By  

/s/ Fredric N. Eshelman

  Chief Executive Officer
  (Principal Executive Officer)
By  

/s/ Daniel G. Darazsdi

  Chief Financial Officer
  (Principal Financial Officer)
By  

/s/ Peter Wilkinson

  Chief Accounting Officer
  (Principal Accounting Officer)

Date: May 5, 2009

 

40

This excerpt taken from the PPDI 8-K filed Apr 22, 2009.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Pharmaceutical Product Development, Inc.
Date: April 21, 2009   By:  

/s/ Daniel Darazsdi

  Name:   Daniel Darazsdi
  Title:   Chief Financial Officer
These excerpts taken from the PPDI 10-K filed Feb 24, 2009.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  PHARMACEUTICAL PRODUCT DEVELOPMENT, INC.
Date: February 24, 2009   By:  /s/ Fredric N. Eshelman, Pharm.D.
  Name:   Fredric N. Eshelman, Pharm.D.
  Title:   Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

/s/ Fredric N. Eshelman, Pharm.D.    Chief Executive Officer and Director   February 24, 2009
Fredric N. Eshelman, Pharm.D.    (Principal Executive Officer)  
/s/ Daniel G. Darazsdi    Chief Financial Officer   February 24, 2009
Daniel G. Darazsdi    (Principal Financial Officer)  
/s/ Peter Wilkinson    Chief Accounting Officer   February 24, 2009
Peter Wilkinson    (Principal Accounting Officer)  
/s/ Stuart Bondurant, M.D.    Director   February 24, 2009
Stuart Bondurant, M.D.     
/s/ Frederick Frank    Director   February 24, 2009
Frederick Frank     
/s/ David L. Grange    Director   February 24, 2009
David L. Grange     
/s/ Catherine M. Klema    Director   February 24, 2009
Catherine M. Klema     
/s/ Terry Magnuson, Ph.D.    Director   February 24, 2009
Terry Magnuson, Ph.D.     
/s/ Ernest Mario, Ph.D.    Director   February 24, 2009
Ernest Mario, Ph.D.     
/s/ John A. McNeill, Jr.    Director   February 24, 2009
John A. McNeill, Jr.     

 

S-1

SIGNATURES

FACE="Times New Roman" SIZE="2">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

































 PHARMACEUTICAL PRODUCT DEVELOPMENT, INC.
Date: February 24, 2009 By:  /s/ Fredric N. Eshelman, Pharm.D.
 Name: Fredric N. Eshelman, Pharm.D.
 Title: Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed
below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 






































































































































































/s/ Fredric N. Eshelman, Pharm.D.  Chief Executive Officer and Director February 24, 2009
Fredric N. Eshelman, Pharm.D.  (Principal Executive Officer) 
/s/ Daniel G. Darazsdi  Chief Financial Officer February 24, 2009
Daniel G. Darazsdi  (Principal Financial Officer) 
/s/ Peter Wilkinson  Chief Accounting Officer February 24, 2009
Peter Wilkinson  (Principal Accounting Officer) 
/s/ Stuart Bondurant, M.D.  Director February 24, 2009
Stuart Bondurant, M.D.   
/s/ Frederick Frank  Director February 24, 2009
Frederick Frank   
/s/ David L. Grange  Director February 24, 2009
David L. Grange   
/s/ Catherine M. Klema  Director February 24, 2009
Catherine M. Klema   
/s/ Terry Magnuson, Ph.D.  Director February 24, 2009
Terry Magnuson, Ph.D.   
/s/ Ernest Mario, Ph.D.  Director February 24, 2009
Ernest Mario, Ph.D.   
/s/ John A. McNeill, Jr.  Director February 24, 2009
John A. McNeill, Jr.   

 


S-1







EX-10.162
2
dex10162.htm
SEVERANCE AGREEMENT DATED JANUARY 1, 2001


Severance Agreement dated January 1, 2001



This excerpt taken from the PPDI 8-K filed Feb 9, 2009.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Pharmaceutical Product Development, Inc.
Date: February 9, 2009   By:  

/s/ Daniel Darazsdi

  Name:   Daniel Darazsdi
  Title:   Chief Financial Officer
This excerpt taken from the PPDI 10-Q filed Nov 5, 2008.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

PHARMACEUTICAL PRODUCT DEVELOPMENT, INC.
(Registrant)
By  

/s/ Fredric N. Eshelman

  Chief Executive Officer
  (Principal Executive Officer)
By  

/s/ Daniel G. Darazsdi

  Chief Financial Officer
  (Principal Financial Officer)
By  

/s/ Peter Wilkinson

  Chief Accounting Officer
  (Principal Accounting Officer)

Date: November 5, 2008

 

45

This excerpt taken from the PPDI 8-K filed Oct 21, 2008.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Pharmaceutical Product Development, Inc.
Date: October 21, 2008   By:  

/s/ Daniel Darazsdi

  Name:   Daniel Darazsdi
  Title:   Chief Financial Officer
This excerpt taken from the PPDI 10-Q filed Aug 7, 2008.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

PHARMACEUTICAL PRODUCT DEVELOPMENT, INC.
(Registrant)
By  

/s/ Fredric N. Eshelman

  Chief Executive Officer
  (Principal Executive Officer)
By  

/s/ Daniel G. Darazsdi

  Chief Financial Officer
  (Principal Financial Officer)
By  

/s/ Peter Wilkinson

  Chief Accounting Officer
  (Principal Accounting Officer)

Date: August 7, 2008

 

43

This excerpt taken from the PPDI 8-K filed Jul 22, 2008.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Pharmaceutical Product Development, Inc.
Date: July 22, 2008   By:  

/s/ Daniel Darazsdi

  Name:   Daniel Darazsdi
  Title:   Chief Financial Officer
This excerpt taken from the PPDI 10-Q filed May 9, 2008.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

PHARMACEUTICAL PRODUCT DEVELOPMENT, INC.
(Registrant)

By

 

/s/ Fredric N. Eshelman

  Chief Executive Officer
  (Principal Executive Officer)

By

 

/s/ Daniel G. Darazsdi

  Chief Financial Officer
  (Principal Financial Officer)

By

 

/s/ Peter Wilkinson

  Chief Accounting Officer
  (Principal Accounting Officer)

Date: May 9, 2008

 

38

This excerpt taken from the PPDI 8-K filed Apr 22, 2008.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Pharmaceutical Product Development, Inc.
Date: April 22, 2008   By:  

/s/ Daniel Darazsdi

  Name:   Daniel Darazsdi
  Title:   Chief Financial Officer
These excerpts taken from the PPDI 10-K filed Feb 26, 2008.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    PHARMACEUTICAL PRODUCT DEVELOPMENT, INC.
Date: February 26, 2008   By:  

/s/ Fredric N. Eshelman, Pharm.D.

  Name:   Fredric N. Eshelman, Pharm.D.
  Title:   Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

/s/ Fredric N. Eshelman, Pharm.D.

Fredric N. Eshelman, Pharm.D.

  

Chief Executive Officer and Director

(Principal Executive Officer)

  February 26, 2008
    

/s/ Daniel G. Darazsdi

Daniel G. Darazsdi

  

Chief Financial Officer

(Principal Financial Officer)

  February 26, 2008
    

/s/ Peter Wilkinson

Peter Wilkinson

  

Chief Accounting Officer

(Principal Accounting Officer)

  February 26, 2008
    

/s/ Stuart Bondurant, M.D.

   Director   February 26, 2008
Stuart Bondurant, M.D.     

/s/ Frederick Frank

   Director   February 26, 2008
Frederick Frank     

/s/ David L. Grange

   Director   February 26, 2008
David L. Grange     

/s/ Catherine M. Klema

   Director   February 26, 2008
Catherine M. Klema     

/s/ Terry Magnuson, Ph.D.

   Director   February 26, 2008
Terry Magnuson, Ph.D.     

/s/ Ernest Mario, Ph.D.

   Director   February 26, 2008
Ernest Mario, Ph.D.     

/s/ John A. McNeill, Jr.

   Director   February 26, 2008
John A. McNeill, Jr.     

 

S-1

SIGNATURES

FACE="Times New Roman" SIZE="2">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 




































  PHARMACEUTICAL PRODUCT DEVELOPMENT, INC.
Date: February 26, 2008 By: 

/s/ Fredric N. Eshelman, Pharm.D.

 Name: Fredric N. Eshelman, Pharm.D.
 Title: Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed
below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 



































































































































































/s/ Fredric N. Eshelman, Pharm.D.

FACE="Times New Roman" SIZE="2">Fredric N. Eshelman, Pharm.D.

  

Chief Executive Officer and Director

(Principal
Executive Officer)

 February 26, 2008
   

/s/ Daniel G. Darazsdi

FACE="Times New Roman" SIZE="2">Daniel G. Darazsdi

  

Chief Financial Officer

(Principal Financial Officer)

 February 26, 2008
   

/s/ Peter Wilkinson

SIZE="2">Peter Wilkinson

  

Chief Accounting Officer

(Principal Accounting
Officer)

 February 26, 2008
   

/s/ Stuart Bondurant, M.D.

  Director February 26, 2008
Stuart Bondurant, M.D.   

/s/ Frederick Frank

  Director February 26, 2008
Frederick Frank   

/s/ David L. Grange

  Director February 26, 2008
David L. Grange   

/s/ Catherine M. Klema

  Director February 26, 2008
Catherine M. Klema   

/s/ Terry Magnuson, Ph.D.

  Director February 26, 2008
Terry Magnuson, Ph.D.   

/s/ Ernest Mario, Ph.D.

  Director February 26, 2008
Ernest Mario, Ph.D.   

/s/ John A. McNeill, Jr.

  Director February 26, 2008
John A. McNeill, Jr.   

 


S-1







EX-10.162
2
dex10162.htm
SEVERANCE AGREEMENT DATED JANUARY 1, 2001


Severance Agreement dated January 1, 2001



This excerpt taken from the PPDI 8-K filed Feb 6, 2008.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Pharmaceutical Product Development, Inc.
Date: February 6, 2008   By:  

/s/ Daniel Darazsdi

  Name:   Daniel Darazsdi
  Title:   Chief Financial Officer
This excerpt taken from the PPDI 10-Q filed Nov 7, 2007.

SIGNATURES

In accordance with the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

PHARMACEUTICAL PRODUCT DEVELOPMENT, INC.

(Registrant)
By  

/s/ Fredric N. Eshelman

  Chief Executive Officer
  (Principal Executive Officer)
By  

/s/ Daniel G. Darazsdi

  Chief Financial Officer
  (Principal Financial Officer)

Date: November 7, 2007

 

36

This excerpt taken from the PPDI 8-K filed Oct 23, 2007.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    Pharmaceutical Product Development, Inc.
Date: October 23, 2007   By:  

/s/ Daniel Darazsdi

  Name:   Daniel Darazsdi
  Title:   Chief Financial Officer
This excerpt taken from the PPDI 10-Q filed Aug 6, 2007.

SIGNATURES

In accordance with the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    PHARMACEUTICAL PRODUCT DEVELOPMENT, INC.
  (Registrant)
By  

/s/ Fredric N. Eshelman

  Chief Executive Officer
  (Principal Executive Officer)
By  

/s/ Peter Wilkinson

  Chief Accounting Officer
  (Principal Financial Officer)

Date: August 6, 2007

 

35

This excerpt taken from the PPDI 8-K filed Jul 17, 2007.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

   

Pharmaceutical Product Development, Inc.

Date: July 17, 2007

    By:  

/s/ Peter Wilkinson

    Name:   Peter Wilkinson
    Title:   Chief Accounting Officer
This excerpt taken from the PPDI 8-K filed Apr 17, 2007.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Pharmaceutical Product Development, Inc.
Date: April 17, 2007   By:  

/s/ Linda Baddour

  Name:   Linda Baddour
  Title:   Chief Financial Officer
This excerpt taken from the PPDI 10-K filed Feb 27, 2007.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    PHARMACEUTICAL PRODUCT DEVELOPMENT, INC.
Date: February 26, 2007   By:  

/s/ Fredric N. Eshelman, Pharm.D.

 
  Name:   Fredric N. Eshelman, Pharm.D.  
  Title:   Chief Executive Officer  

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

/s/ Fredric N. Eshelman, Pharm.D.

Fredric N. Eshelman, Pharm.D.

  

Chief Executive Officer and Director

(Principal Executive Officer)

  February 26, 2007

/s/ Linda Baddour

Linda Baddour

  

Chief Financial Officer

(Principal Financial and Accounting Officer)

  February 26, 2007

/s/ Stuart Bondurant, M.D.

Stuart Bondurant, M.D.

   Director   February 26, 2007

/s/ Marye Anne Fox, Ph.D.

Marye Anne Fox, Ph.D.

   Director   February 26, 2007

/s/ Frederick Frank

Frederick Frank

   Director   February 26, 2007

/s/ David L. Grange

David L. Grange

   Director   February 26, 2007

/s/ Catherine M. Klema

Catherine M. Klema

   Director   February 26, 2007

/s/ Terry Magnuson, Ph.D.

Terry Magnuson, Ph.D.

   Director   February 26, 2007

/s/ Ernest Mario, Ph.D.

Ernest Mario, Ph.D.

   Director   February 26, 2007

/s/ John A. McNeill, Jr.

John A. McNeill, Jr.

   Director   February 26, 2007

 

S-1

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki